The article suggests selling Clorox (CLX) due to its underperformance compared to the S&P 500, despite staying on track with the overall market. The stock has gained 5.8% over the last six months, which is lower than the S&P 500's 7.7% return. An alternative stock is not explicitly mentioned in the article.